Literature DB >> 2208000

Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx.

F Esteban1, F Ruiz-Cabello, A Concha, M Perez Ayala, M Delgado, F Garrido.   

Abstract

The 4F2 antigen is a cell-membrane glycoprotein which arises early in the G0-G1 phases of the cell cycle. This molecule is present in all established human cell lines and most malignant human cells. The authors used an indirect immunophosphatase method to study 50 squamous cell carcinomas of the larynx and ten lymph-node metastases, corresponding to six primary tumors, for 4F2 expression. The tumors showed several patterns of 4F2 staining which were correlated with different behaviors and prognoses of the neoplasms. Three different patterns (no staining, peripheral staining, and diffuse 4F2 expression) are described as are their relationships with metastatic behavior of the carcinomas. Tumors with metastases were found only in the third group (P = 0.0001). These results led to the following conclusions: (1) the 4F2 antigen is present in squamous cell carcinomas; (2) its distribution reflects the tumor-spreading pattern; and (3) it correlates with differentiation and metastatic behavior.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208000     DOI: 10.1002/1097-0142(19901001)66:7<1493::aid-cncr2820660710>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice.

Authors:  Hang Thi Thu Nguyen; Guillaume Dalmasso; Leif Torkvist; Jonas Halfvarson; Yutao Yan; Hamed Laroui; Doron Shmerling; Tiziano Tallone; Mauro D'Amato; Shanthi V Sitaraman; Didier Merlin
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

2.  Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Hisao Imai; Kimihiro Shimizu; Noriko Yanagitani; Noriaki Sunaga; Takeshi Hisada; Osamu Kawashima; Yosuke Kamide; Tamotsu Ishizuka; Yoshikatsu Kanai; Takashi Nakajima; Masatomo Mori
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

Review 3.  Homeostatic and innate immune responses: role of the transmembrane glycoprotein CD98.

Authors:  Hang Thi Thu Nguyen; Didier Merlin
Journal:  Cell Mol Life Sci       Date:  2012-03-30       Impact factor: 9.261

Review 4.  CD98 at the crossroads of adaptive immunity and cancer.

Authors:  Joseph M Cantor; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2012-04-12       Impact factor: 5.285

5.  CD98hc facilitates B cell proliferation and adaptive humoral immunity.

Authors:  Joseph Cantor; Cecille D Browne; Raphael Ruppert; Chloé C Féral; Reinhard Fässler; Robert C Rickert; Mark H Ginsberg
Journal:  Nat Immunol       Date:  2009-03-08       Impact factor: 25.606

6.  Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: implications in molecular imaging.

Authors:  Yixuan Yang; Weiyi Toy; Lee Yee Choong; Peiling Hou; Hassan Ashktorab; Duane T Smoot; Khay Guan Yeoh; Yoon Pin Lim
Journal:  J Proteome Res       Date:  2012-11-26       Impact factor: 4.466

7.  Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior.

Authors:  Daniela Bianconi; Elisabeth Fabian; Merima Herac; Markus Kieler; Johannes Thaler; Gerald Prager; Matthias Unseld
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

8.  Different cDNA microarray patterns of gene expression reflecting changes during metastatic progression in adenoid cystic carcinoma.

Authors:  Dan Huang; Wantao Chen; Ronggen He; Fan Yu; Zhiyuan Zhang; Weiliu Qiu
Journal:  World J Surg Oncol       Date:  2003-12-19       Impact factor: 2.754

9.  Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets.

Authors:  Robyn A A Oldham; Mary L Faber; Theodore R Keppel; Amanda R Buchberger; Matthew Waas; Parameswaran Hari; Rebekah L Gundry; Jeffrey A Medin
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.